Importer of Controlled Substances Application: ABBVIE LTD; Correction

---
identifier: "/us/fr/2017-28176"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Importer of Controlled Substances Application: ABBVIE LTD; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2017-28176"
section_name: "Importer of Controlled Substances Application: ABBVIE LTD; Correction"
positive_law: false
currency: "2017-12-29"
last_updated: "2017-12-29"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "2017-28176"
document_type: "notice"
publication_date: "2017-12-29"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "82 FR 61795"
fr_volume: 82
docket_ids:
  - "Docket No. DEA-392"
fr_action: "Notice; correction."
---


#  Importer of Controlled Substances Application: ABBVIE LTD; Correction

**ACTION:**

Notice; correction.

**SUMMARY:**

The Drug Enforcement Administration (DEA) published a document in the *Federal Register* of December 1, 2017, concerning a notice of application that inadvertently misstated what the firm plans to do with imported tapentadol.

**Correction**

In the *Federal Register* of December 1, 2017, in FR Doc. 2017-25921 (82 FR 230), on page 230, in the second column, the last paragraph, correct the first sentence to read: The company plans to import bulk tapentadol (9780) to manufacture dosage form tapentadol (9780) for distribution to its customers.

Demetra Ashley,

Acting Assistant Administrator.